Results 71 to 80 of about 64,446 (303)

Direct Oral Anticoagulants: A Quick Guide [PDF]

European Cardiology Review, 2017
Vitamin K antagonists, such as warfarin, have been the anticoagulants of choice for many years for patients with AF and other thrombotic conditions. The introduction of direct oral anticoagulants (DOACs) as alternatives represents a major advance in anticoagulation.
Sikorska, Julia, Uprichard, James
openaire   +2 more sources

Translation of a physiologically‐based pharmacokinetic model for dabigatran etexilate to the design of a safety and efficacy study in post‐partum women

British Journal of Clinical Pharmacology, EarlyView.
Aims To translate a PBPK model developed for the direct oral anticoagulant, dabigatran etexilate, the prodrug of dabigatran, based on data obtained from healthy men to healthy non‐pregnant, pregnant and post‐partum women. To evaluate safety and efficacy of dabigatran etexilate in post‐partum women using simulations and design a future clinical study to
Kayode Ogungbenro, Lorna Aucott, Farhad Kamali, Paul Ayuk   +3 more
wiley   +1 more source

Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy. [PDF]

, 2017
We present the case of a patient with a deep vein thrombosis (DVT) who failed rivaroxaban therapy. Our patient initially presented with left lower extremity edema, erythema, and pain.
Adashek, Jacob, Ben-Zur, Uri M, Nagar, Menachem, Pietras, Richard J, Toomari, Nojan, Yaghoubian, Jonathan M, Yaghoubian-Yazi, Bahareh   +6 more
core   +5 more sources

Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer

British Journal of Clinical Pharmacology, EarlyView.
Aims Treatment with enzalutamide in prostate cancer is challenging due to its high potential for drug–drug interactions, particularly in the typically older population of patients with frequent comorbidities treated with multiple drugs, such as anticoagulants.
Catharina J. P. Op 't Hoog, Niven Mehra, Anouk van Kleef, Diederik M. Somford, Inge M. van Oort, Alex L. T. Imholz, Paul Hamberg, Nielka P. van Erp, Emmy Boerrigter   +8 more
wiley   +1 more source

Developing a complex intervention to improve prescribing safety in primary care:mixed methods feasibility and optimisation pilot study [PDF]

, 2014
Objectives (A) To measure the extent to which different candidate outcome measures identified high-risk prescribing that is potentially changeable by the data-driven quality improvement in primary care (DQIP) intervention.(B) To explore the value of ...
Dreischulte, Tobias, Grant, Aileen M., Guthrie, Bruce   +2 more
core   +7 more sources

Comparative effectiveness and safety of oral anticoagulants in patients with atrial fibrillation using antiarrhythmic drugs: An international cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aim Our international cohort study assessed the comparative effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) among patients with non‐valvular atrial fibrillation (NVAF) using antiarrhythmic drugs. Methods Using the United Kingdom's (UK's) Clinical Practice Research Datalink Aurum and Québec claims data, we
Fabian Maximilian Meinert, Jenny Dimakos, Ying Cui, Kristian B. Filion, Christel Renoux, Antonios Douros   +5 more
wiley   +1 more source

Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations [PDF]

Journal of Stroke, 2018
Development of direct oral anticoagulants and their antidotes has led to the need to reconsider the eligibility of acute stroke patients who have been taking oral anticoagulants for intravenous thrombolysis.
Kazunori Toyoda, Hiroshi Yamagami, Masatoshi Koga   +2 more
doaj   +1 more source

Cancer and thrombosis: Managing the risks and approaches to thromboprophylaxis [PDF]

, 2006
Patients with cancer are at increased risk of venous thromboembolism (VTE) compared with patients without cancer. This results from both the prothrombotic effects of the cancer itself and iatrogenic factors, such as chemotherapy, radiotherapy, indwelling
Altinbas M, Athanasoulis CA, Bergqvist D, Bergqvist D, Buller HR, Clagett PG, Da Silva MS, Decousus H, ENOXACAN Study Group, Falanga A, Geerts WH, Gitter MJ, Goldenberg N, Gomes MPV, Green D, Haas S, Heit JA, Hettiarachchi RJK, Hull R, Hutten BA, International Multicentre Trial, Johnson MJ, Kakkar VV, Karthaus M, Koopman MMW, Levine MN, Mousa S A, Mousa SA, Prandoni P, Rasmussen MS, Rickles FR, Sallah S, Samama M, Siragusa B, The Columbus Investigators, White RH, Zacharski LR   +36 more
core   +1 more source

Hypnotic doses of fazamorexant induced less impairment on balance and cognition than zolpidem in healthy younger and elderly individualse

British Journal of Clinical Pharmacology, EarlyView.
Aims Fazamorexant is a dual orexin receptor antagonist being developed for the treatment of insomnia. This study aims to determine the dose‐exposure‐response relationship of single‐dose fazamorexant vs. zolpidem in young adult and elderly healthy Chinese volunteers. Methods This single‐centre, randomized, double‐blind, double‐dummy, placebo‐ and active‐
Chen Xia, Huang Xingxing, Jin Lu, Wang Ruwei   +3 more
wiley   +1 more source

Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? [PDF]

, 2018
© 2018 Bentham Science PublishersBACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.
Akhtar, Zaki, Farag, Mohamed, Gorog, Diana Adrienne, Spinthakis, Nikolaos   +3 more
core   +2 more sources